Translating GPCR Insights into Successful Medicines by Overcoming Target Engagement & Biomarker Challenges
- Developing predictive biomarkers to identify oncology patients most likely to respond to GPCR-targeted ADCs or radio-conjugates, enabling precision therapy selection
- Leveraging human-derived tumour models (patient-derived xenografts, resistant models) to translate GPCR biology into clinically relevant drug responses
- Implementing advanced target engagement assays to confirm ADC binding, internalisation, and payload release within the tumour microenvironment